Kura Oncology
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 142
- Market Cap
- $1.5B
- Website
- http://www.kuraoncology.com
- Introduction
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors...
A Study of Ziftomenib, an Oral Menin Inhibitor, in Combination with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)
- Conditions
- Interventions
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 157
- Registration Number
- NCT06655246
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT06026410
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
🇺🇸University of Southern California, Los Angeles, California, United States
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 171
- Registration Number
- NCT06001788
- Locations
- 🇺🇸
The University of Kansas, Kansas City, Kansas, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Prisma Health, Greenville, South Carolina, United States
Expanded Access to Ziftomenib
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Kura Oncology, Inc.
- Registration Number
- NCT05738538
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination with Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients with AML
- Conditions
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 212
- Registration Number
- NCT05735184
- Locations
- 🇺🇸
Moores UC San Diego Cancer Center, La Jolla, California, United States
🇺🇸USC University of Southern California / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA - Bowyer Oncology Center, Los Angeles, California, United States
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Kura Oncology, Inc.
- Registration Number
- NCT05693090
- Locations
- 🇺🇸
The Valley Hospital, Ridgewood, New Jersey, United States
🇺🇸Providence Medical Group, Santa Rosa, California, United States
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04997902
- Locations
- 🇺🇸
University of Maryland School of Medicine (Marlene and Stewart Greenebaum Comprehensive Cancer Center), Baltimore, Maryland, United States
🇺🇸Johns Hopkins University School of Medicine (Sidney Kimmel Comprehensive Cancer Center), Baltimore, Maryland, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04865159
- Locations
- 🇺🇸
NEXT Oncology, San Antonio, Texas, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
Expanded Access to Tipifarnib
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Kura Oncology, Inc.
- Registration Number
- NCT04809233
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 199
- Registration Number
- NCT04067336
- Locations
- 🇺🇸
UCLA Bowyer Oncology Center, Los Angeles, California, United States
🇺🇸University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸University of Southern California, Los Angeles, California, United States